Ann Dermatol.  2023 May;35(Suppl1):S117-S121. 10.5021/ad.21.078.

Progression of Pre-Existing Vitiligo during Secukinumab Treatment for Psoriasis

• Kim JC
• Lee ES

• KMID: 2542755
• DOI: http://doi.org/10.5021/ad.21.078

Abstract

Vitiligo has been considered an unexplained paradoxical phenomenon during biologics use. Herein, we report an adult case of progression of pre-existing vitiligo during secukinumab treatment for psoriasis, and we also examined the immunohistochemical changes in relation to biologics use. He was being administered monthly secukinumab of 300 mg dose for 2 years, and all psoriatic lesions were cleared, but pre-existing hypopigmented lesions became more distinct and larger than before unlike when using adalimumab. A skin biopsy of the hypopigmented lesion showed loss of epidermal melanocytes and absence of gp100 immune activities, and he was finally diagnosed with progression of pre-existing vitiligo. Immunohistochemical staining of vitiligo lesion showed decrease in interleukin-17 and tumor necrosis factor-α and increase in CD8+ T cells, interferon-γ, and CXCL10 after the use of secukinumab. In this study, we suggest that biologics-induced cytokine imbalance play a critical role in vitiligo progression in patients with chronic inflammatory diseases, including psoriasis.

Keyword

Biologics; Interleukin-17; Psoriasis; Secukinumab; Vitiligo